Macrophages have an important role in the pathogenesis of most chronic inflammatory diseases. A means of noninvasively quantifying macrophage migration would contribute significantly towards our understanding of chronic inflammatory processes and aid the evaluation of novel therapeutic strategies. We describe the use of a perfluorocarbon tracer reagent and in vivo 19 F magnetic resonance imaging (MRI) to quantify macrophage burden longitudinally. We apply these methods to evaluate the severity and three-dimensional distribution of macrophages in a murine model of inflammatory bowel disease (IBD). MRI results were validated by histological analysis, immunofluorescence and quantitative real-time polymerase chain reaction. Selective depletion of macrophages in vivo was also performed, further validating that macrophage accumulation of perfluorocarbon tracers was the basis of 19 F MRI signals observed in the bowel. We tested the effects of two common clinical drugs, dexamethasone and cyclosporine A, on IBD progression. Whereas cyclosporine A provided mild therapeutic effect, unexpectedly dexamethasone enhanced colon inflammation, especially in the descending colon. Overall, 19 F MRI can be used to evaluate early-stage inflammation in IBD and is suitable for evaluating putative therapeutics. Due to its high macrophage specificity and quantitative ability, we envisage 19 F MRI having an important role in evaluating a wide range of chronic inflammatory conditions mediated by macrophages.
Inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis are premalignant conditions that significantly increase the risk of colorectal cancer. 1 The degree of risk of colorectal cancer depends on the anatomical extent, duration and age of onset of IBD. Computed assisted tomography and magnetic resonance imaging (MRI) are non-invasive imaging techniques increasingly being used for evaluation of IBD, 2 and the diagnosis is commonly confirmed by colonoscopic biopsy. 3 Colonoscopic biopsy is invasive and requires multiple tissue bites for diagnosis and may cause patient discomfort. Longitudinal, non-invasive quantification of bowel inflammation could potentially provide substantial benefits to the diagnosis and therapeutic monitoring of IBD and the development of new therapeutics.
Resident macrophages in the colon have a key role in the homeostasis of the bowel, 4, 5 and macrophages derived from blood monocytes are important mediators of chronic inflammation in IBD along with Th1-and Th2-type T cells. [4] [5] [6] [7] [8] [9] [10] [11] [12] Thus, non-invasive quantification of macrophage activity in vivo could potentially predict the extent, severity and treatment response in IBD.
Among non-invasive imaging techniques, MRI is often preferable because it does not involve ionizing radiation, has reasonably high spatial and temporal resolution and has excellent soft tissue contrast. With MRI, bowel inflammation is commonly assessed by measuring wall thickness in T 2 -weighted and Gd-enhanced T 1 -weighted images. 13 However, bowel wall thickness does not differentiate between active and inactive disease, and Gd-induced contrast is nonspecific due to leaky exudation into the bowel wall. Cellular MRI using superparamagnetic iron-oxide nanoparticles, which are taken up by the reticuloendothelial system, has been used to study macrophage burden at inflammatory sites in animal models.
14 Cellular MRI using iron-oxides has potentially high sensitivity, but its use for IBD can be challenging due to the negative contrast produced by labeled cells, the high background 1 H signal and pronounced intrinsic contrast in bowel and abdominal regions. Moreover, the relationship between signal intensity and concentration of contrast agents is non-linear, making quantitative analyses of disease burden from images challenging. 19 F MRI of inflammation using perfluorocarbon (PFC) 'tracer' emulsions is an emerging approach that yields positive contrast images and has been used to detect inflammatory loci in animal models. [15] [16] [17] [18] [19] Due to the absence of detectable endogenous 19 F in biological tissues, there is no background, and inflammatory foci appear hyperintense in spin density-weighted images. In addition, 19 F MRI signal can be readily quantified by integrating the signal in regions of interest (ROIs), which is linearly proportional to the macrophage burden. 20 Interleukin-10 À/À (IL-10
) mice develop colitis with a pathology that closely resembles human IBD in disease manifestation and course. [21] [22] [23] As observed in human IBD, IL-10 À/À mice require intestinal bacteria to develop IBD. Mice develop a progressive chronic inflammation that ultimately may progress into colitis-associated colon cancer. IL-10 gene polymorphism has been implicated in human IBD in several studies. 24, 25 IBD in IL-10 À/À mice run a variable course that can be synchronized by administration of piroxicam. 26 Macrophages are necessary mediators of inflammation in murine IBD. In IL-10 À/À mice, elimination of intestinal macrophages reduces the development of colitis; 27 a similar function for macrophages was observed in other mouse models of IBD such as dextran sulphate sodium (DSS)-induced colitis. 28 In this study, we evaluated the use of 19 F cellular MRI using PFC emulsion to detect and quantify the severity and extent of bowel inflammation in vivo. These studies utilized a piroxicam-induced IBD model in IL-10 À/À mice. Using confocal immunofluorescence microscopy and quantitative real-time PCR (qRT-PCR) of macrophage RNA, we demonstrate that macrophage activity in the colon forms the basis of 19 F signals detected in the colon. This was further confirmed by selectively ablating macrophages in vivo and examining the consequences via 19 F MRI and immunofluorescence. We then examined the ability of 19 F MRI to detect the efficacy of putative IBD therapeutics, including dexamethasone and cyclosporine A (CsA). Our studies confirm that 19 F MRI is an effective and sensitive non-invasive technique for quantifying early stages of inflammation in IBD and monitoring treatment response. Overall, we believe that these methodologies will be useful for many other inflammatory diseases and malignancies where macrophages have an important role.
MATERIALS AND METHODS
Mouse Model of IBD Animal protocols were approved by the Carnegie Mellon University IACUC. All mice received humane care in compliance with the Guide for the Care and Use of Laboratory Animals, published by the NIH. Transgenic IL-10 À/À mice on C57/Bl6 background were purchased from Jackson laboratories (Bar Harbor, ME, USA). Female 9-12-week-old mice (n ¼ 22) were fed with piroxicam-doped chow (220 ppm) for 14 days to synchronize IBD induction. To detect early bowel irritation, mice were tested for the presence of occult blood in stool using a hemoccult test (Hemoccult Sensa, Beckman Coulter, Brea, CA, USA). After 2 weeks, the piroxicam diet was discontinued, and mice were placed on normal chow. Animal weights were monitored daily throughout the entire study period.
IBD Treatment
The first treatment group (n ¼ 5) received clodronate liposomes delivered intraperitoneally (0.1 ml per dose). Clodronate was a gift from Roche Diagnostics GmbH, Mannheim, Germany, and was formulated into liposomes using methods previously described. 29 The first dose was administered 2 days prior to piroxicam treatment, followed by two additional doses separated by 5 days after the start of piroxicam exposure. The second treatment group (n ¼ 5) received dexamethasone intraperitoneally (1.2 mg/kg) daily for 2 weeks. A third treatment group (n ¼ 4) was administered CsA intraperitoneally (10 mg/kg) daily for 2 weeks. For both dexamethasone and CsA, the initial doses were administered 2 days prior to piroxicam treatment.
Administration of PFC Emulsion
On day 15, mice were injected with 0.2 ml of a commercial PFC emulsion formulation (VS-1000H, Celsense, Pittsburgh, PA, USA) intravenously via the tail vein using a 28 G needle. This emulsion formulation contains 30% v/v perfluoropolyether with a mean emulsion droplet diameter of 145 nm according to the manufacturer. To aid in post-MRI histological analysis, the PFC emulsion was rendered fluorescent prior to injection via a premix step of the PFC emulsion with a lipophilic dialkylcarbocyanine (DiI, V22885, Molecular Probes, Eugene, OR, USA) fluorophore, as previously described. 20, 30 In Vivo MRI Mice were imaged on days 2, 9, 16, 23 and 30 after PFC injection. Imaging was performed using an 11. 7 T vertical bore microimaging system (Bruker Biospin, Billerica, MA, USA 
Colon Thickness Measurement
Colon thickness was measured on day 2 post injection using the image display and processing module in Paravision 4.0. software (Bruker Biospin). For each subject, maximum wall thickness of ascending and descending colon was calculated using the interactive distance measurements tool in Paravision. The mean thickness and the s.e.m. were calculated by combining the data obtained from different subjects in each group.
MRI of the Fixed Colon Tissues
At the completion of the longitudinal study, mice were euthanized, the colon tissue excised, cleaned in phosphatebuffered saline, and then fixed in 4% paraformaldehyde. The fixed colon tissues were further imaged using extremely highresolution MRI to further elucidate lesion topology along the length of the bowel. A thin glass rod was inserted into the lumen to straighten the fixed colon, and samples were placed into a sealed 15 ml plastic tube containing phosphatebuffered saline doped with 1 mg/ml of Feridex iron-oxide nanoparticles (AMAG Pharmaceuticals, Lexington, MA, USA) to attenuate the background 1 H signal. The sample was placed in a 10-mm diameter birdcage coil and imaged in 3D at 11.7 T (Bruker). The T 2 -weighted 1 H images were obtained using a spin echo sequence (parameters: TR/TE ¼ 1000/ 10 ms, matrix size ¼ 512 Â 256, FOV ¼ 3 Â 1.1 cm, slice thickness ¼ 1 mm, NA ¼ 4, slices ¼ 6). 19 F images were obtained using a RARE sequence (parameters: RARE factor ¼ 8, TR/TE ¼ 1000/11 ms, matrix size ¼ 64 Â 32, FOV ¼ 3 Â 1.1 cm, slice thickness ¼ 1 mm, NA ¼ 64, slices ¼ 6).
Histology and Immunofluorescence
Colon tissues were fixed in 2% PFA in PBS and analyzed using histology and immunofluorescence (n ¼ 3 mice per group). Segments of the fixed colon tissues were embedded in paraffin, cut into 5 mm-thick transverse sections, and stained with hematoxylin and eosin (H&E). The H&E-stained slides were evaluated by an independent pathologist blinded to the groups studied. Twelve sections from different parts of the entire length of the colon were evaluated at high power magnification (400 Â ). Briefly, the degree of inflammation present was graded on a scale of 0 to 4 as follows: (0) No inflammatory cell infiltration, (1) few scattered inflammatory cells in lamina propria, (2) more obvious infiltrate with some extension into submucosa, (3) expansion of lamina propria with a mixed infiltrate with intraepithelial infiltration and extension to submucosa without obvious ulceration and (4) acute inflammation with ulceration.
For immunofluorescence, colon tissues from untreated (n ¼ 3) and clodronate-treated (n ¼ 2) groups were used. In untreated group, colon sections were stained on day 2 and day 30 after PFC administration. In clodronate-treated groups, colon sections were stained on day 2 after the first imaging session. Fixed colon tissues were frozen in liquid nitrogen and embedded in Tissue-Tek optimal cutting temperature compound (Ted Pella, Redding, CA, USA). Tissue blocks were cut into 7 mm-thick sections using a cryotome at À30 1C Sections were mounted on glass slides and briefly washed with PBS and permeabilized by 0.1% Triton X-100 (Sigma-Aldridge, St Louis, MO, USA). Immunostaining was performed using primary antibodies against macrophages (F4/80), neutrophils (7/4), monocytes (Ly 6c) and endothelial cells (CD31). All primary antibodies were obtained from AbD Serotec, Raleigh, NC, USA. Secondary antibodies conjugated with Alexa 488 (AbD Serotec) were used to probe the marker expression levels. Confocal microscopy of the tissues was performed to examine the cellular colocalization of Alexa 488 with the PFC-DiI droplets using an Olympus Fluoview 1000 confocal microscope (Olympus, Center Valley, PA, USA).
Nuclear Magnetic Resonance (NMR) Spectroscopy NMR spectroscopy of bowel samples was used to assay the total 19 F content. Freshly isolated colon samples (n ¼ 2)) from the untreated group were immersed in RNAlater Imaging inflammation in vivo usingsolution (Ambion, Austin, TX, USA), cut longitudinally and cleaned. RNAlater was used to preserve the sample RNA for subsequent PCR analysis. Each colon was divided into six segments, with three each in the ascending and descending colon, and each segment was weighed. Tissue segments, immersed in RNAlater, were loaded into 5 mm NMR tubes. The specimen size was small enough to fit entirely within the homogenous receptive field of the NMR probe so that all 19 F was detected. A 5 ml, 1% v/v, aliquot of trifluoroacetic acid (TFA) was placed in a flame-sealed 1 mm diameter quartz capillary tube and positioned inside the NMR tube next to the tissue sample; this TFA reference contained a total of N F ¼ 1.2 Â 10 18 fluorine atoms. A one-dimensional 19 F NMR spectrum was acquired for each sample at 470 MHz (Bruker) with 32 averages and a delay time of 5 s. Two distinct peaks were observed at approximately À76 ppm for TFA and À91.5 ppm for the PFC. The total fluorine content (C F ) of the sample was calculated from the integrated peak areas for the PFC (I PFC ) and TFA (I TFA ) reference using the formula C F ¼ I PFC N F /I TFA . Results were normalized to the tissue weight, yielding the 19 F atoms per gram tissue.
qRT-PCR After NMR, quantitative PCR analysis of the same colon samples was performed to assay macrophage burden. Tissue RNA was extracted using trizol/chloroform following manufacturer's instruction (Invitrogen, Carlsbad, CA, USA). RNA recovery was measured using a Smart-Spec spectrophotometer (Bio-Rad, Hercules, CA, USA). A 5 mg RNA aliquot was used for first-strand cDNA synthesis using Superscript Reverse Transcriptase (Invitrogen) with anchored primers (oligo-dT 23 ) following the manufacturer's protocol. Taqman qRT-PCR probes and primers for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and CD68 were designed using Vector NT (Invitrogen À/À mice (n ¼ 10) was induced by feeding with piroxicam-doped chow for 14 days. At the end of the induction period, the IL-10 À/À mice were injected intravenously with PFC emulsion. Mice were imaged longitudinally starting from 2 days post injection. 19 F MRI revealed a patchy PFC distribution in the colon wall ( Figure 1a) . Control C57/Bl6 mice (n ¼ 4), also receiving intravenous PFC, displayed no significant 19 F signal in colon wall (Figure 1b) . In all mice, 19 F signal was detected in spleen and liver. Axial slices from the entire abdomen in the IL-10 À/À mice were stacked and rendered in 3D to visualize the extent and distribution of PFC in the colon in vivo (Figure 1c) . We confirmed the in vivo results using high-resolution MRI of the excised, fixed colon (Figure 1d ). The appearance of the PFC distribution in the colon wall was smooth and continuous in certain bowel regions, but in other regions it appeared patchy with distinct foci (Figure 1d ).
Quantitative Analysis of Bowel Inflammation by
1 H and 19 F MRI Bowel inflammation was assessed initially by measuring the thickness of bowel wall in T 2 -weighted 1 H anatomic scans (Figure 2a) . Image analysis revealed that in ascending colon, the mean thickness of the colonic wall was 1.475±0.12 mm in IL-10 À/À mice compared with 0.55±0.05 mm in control mice (P ¼ 0.0008, t-test). In descending colon, wall thickness was 0.53±0.1 mm in IL-10 À/À mice compared with 0.39± 0.05 mm (P ¼ 0.16, t-test) in control mice (Figure 2b) .
The IL-10 À/À mice were longitudinally imaged for 30 days following PFC emulsion administration (n ¼ 4). From the image data, the PFC distribution and apparent number of 19 F atoms present in the colon wall in various regions was quantified relative to a reference capillary placed along the animal's torso containing 2.34 Â 10 17 19 F atoms/mm 3 ( Figure  2b) . 31 In the majority of mice, the PFC accumulation was higher in ascending colon compared with descending colon. The 19 F signal peaked at day 9 after injection, and by day 30 the signal decreased to the level observed on day 2. In control C57/Bl6 mice, no 19 F signal was observed in the colon in any of the imaging sessions. There was strong 19 F signal found in the liver and spleen. The 19 F signal in the ascending colon (square) was higher than descending colon (circle) on all days. Peak signal intensity was observed on day 9 in ascending colon, and by day 30 the signal decreased to the level observed on day 2. Control C57/Bl6 mice did not show any 19 F signal in the colon (data not shown). Statistical analyses were performed using one-tailed t-test.
Imaging inflammation in vivo using

Histology of Colon Reveals Mucosal Hyperplasia and Infiltration of Mononuclear Cells
At the end of induction period, mice were euthanized and colon tissues were excised. Average weight of ascending colon (P ¼ 0.004, t-test) and descending colon (P ¼ 0.001, t-test) in IL-10 À/À mice was significantly higher than that of the colon in control mice (Figure 3a) . Histological sections stained with H&E revealed inflammation in the bowel wall characterized by mucosal hyperplasia, goblet cell depletion and infiltration of inflammatory mononuclear cells (Figure 3b ). Lymphocytes and macrophages were the predominant infiltrates. In a blind histopathological analysis, the average colitis score in the IL-10 À/À mice was significantly higher compared with control mice (Figure 3c , P ¼ 0.012, t-test). Colon inflammation was predominantly observed in ascending colon.
Macrophage Burden Forms the Basis of the 19 F MRI Signals in the Bowel
We characterized the cellular basis of the 19 F signal in the colon by confocal immunofluorescence microscopy. Prior to injection, the PFC emulsion was pre-labeled with a DiI fluorophore. 20 DiI (red), adherent to the PFC droplets, was present exclusively within F4/80 macrophages in the colon from day 2 to day 30 (green, Figures 4a and b) . Approximately 15-20% of the macrophages in the colonic wall contained PFC droplets. The correlation coefficient between F4/80-positive macrophages and observed PFC droplets is 0.99. The PFC droplets did not colocalize with neutrophils, endothelial cells (CD31) or ly6C hi cells (Figures 4c and d) . These data suggest that 19 F MRI exclusively measures macrophage content in the colon, and quantification of the apparent 19 F signal reflects macrophage burden. We further characterized the basis of 19 F signal in the bowel by directly correlating the level of macrophage mRNA (CD68) expression with the total 19 F signal in colon segments. Excised colon was divided into six segments. The total 19 F signal in a colon segment was quantified by 19 F NMR spectroscopy and normalized to the weight of each segment.
The macrophage load in the segment was quantified by qRT-PCR analysis for the expression of macrophage marker CD68 normalized to the expression of the house-keeping gene GAPDH. The Intraperitoneal treatment of clodronate liposomes ablates circulating monocytes in the blood and resident macrophages in the abdomen. 29 We observed that clodronate liposome treatment significantly reduced 19 F signal in ascending (P ¼ 0.001, t-test) and descending colon (P ¼ 0.05 t-test) compared with the untreated mice (Figure 5a, n ¼ 3) . Histological analysis showed significant decrease in the colitis score in the ascending colon (P ¼ 0.013, t-test) after clodronate liposome treatment. The decrease in colitis score was less apparent in the descending colon (P ¼ 0.06, t-test), probably due to the low initial inflammatory response in the descending colon (Figure 5b, n ¼ 3) . In addition, immunofluorescence revealed a decrease in macrophage density in the colon, and there was no apparent accumulation of PFC-DiI in the macrophages (Figure 5c ).
Impact of Dexamethasone and CsA on the Development of Colitis in IL-10
À/À Mice We tested the prophylactic effects of commonly used clinical drugs on the induction of colitis in IL-10 À/À mice, with the goal of evaluating whether PFC and 19 F MRI could detect putative therapeutic effects in vivo. Prophylactic treatment with dexamethasone (n ¼ 5) showed a significant increase in the accumulation of PFC in the colon, especially in the Imaging inflammation in vivo using 19 descending colon (P ¼ 0.048 t-test), suggesting that dexamethasone does not prevent the development of colitis at the dose tested in these mice (Figure 6a ). Prophylactic treatment with CsA (n ¼ 4) showed a trend towards reduced PFC accumulation in the descending colon, but the effect was not statistically significant ( Figure 6a , P ¼ 0.1 t-test). In the ascending colon, both dexamethasone (P ¼ 0.1, t-test) and CsA (P ¼ 0.2, t-test) did not exhibit any therapeutic effects. compared with untreated (white). In the ascending colon, both dexamethasone (gray, P ¼ 0.1) and CsA (P ¼ 0.2) did not exhibit any therapeutic effects. (b) Colitis score in the descending colon in dexamethasone-treated mice was significantly increased (P ¼ 0.005), and colitis score in CsA-treated mice (P ¼ 0.06) was decreased. There was no significant change in colitis score in the ascending colon for dexamethasone-(P ¼ 0.3) and CsA-treated (P ¼ 0.3) mice compared with untreated controls. Statistical analyses were performed using one-tailed t-test.
Histological analysis showed an increase in colitis score in dexamethasone-treated mice (Figure 6b , P ¼ 0.005, t-test) and a decrease in colitis score in CsA-treated mice in the descending colon (Figure 6b , P ¼ 0.06, t-test). In ascending colon, there was no significant change in colitis score in both dexamethasone (P ¼ 0.3, t-test) and CsA-treated (P ¼ 0.3, t-test) mice compared with untreated controls.
DISCUSSION
In this paper, we show that macrophage activity associated with inflammation in the colon of IL-10 À/À mice can be non-invasively detected and scored using 19 F MRI utilizing a novel PFC tracer-imaging agent. Using immunofluorescence, qRT-PCR and in situ macrophage ablation, we demonstrate that PFC is localized within macrophages and that the cell quantity is reflected in the magnitude of the measured 19 F signal in the colon. Furthermore, we show that the method is suitable to assay the effects of putative therapeutics used to treat colitis. The total imaging time for 19 F MRI used in this work was B8 min, which is practical for routine preclinical studies and testing of therapeutic test articles.
The non-invasive nature of 19 F MRI provides rapid assessment of the extent and 3D distribution of bowel inflammation in a manner that is not feasible by invasive procedures like biopsy or necropsy. Importantly, the extent of colon inflammation and age of onset are key factors that determine the progression of colitis into colitis-associated colon cancer. 1 Because there is no endogenous MRI-detectable fluorine in the bowel, the only source of 19 F signal is inflammation-associated macrophage activity, and thus detection is unambiguous. The absence of background 19 F enables reliable lesion quantification, which is often challenging with various 1 H MRI modalities. In our study, it was difficult to assess inflammation by measuring bowel thickness by 1 H MRI alone, especially in descending colon where inflammation was mild. The 19 F signals were readily detected in the descending colon even when the inflammation was mild. Moreover, 3D reconstructions of bowel lesions are feasible without manual segmentation, offering views of the colon within the context of the whole abdominal cavity that provide an accurate picture of the extent and distribution of the diseased regions.
As a class of molecules, many PFCs are considered safe for in vivo applications. Several PFCs have been used in human clinical trials as artificial oxygen carriers. 32 The blood half-life of the PFC used in this study is B12 h in mice. In tissues, PFC accumulates in the reticuloendothelial system initially and is slowly cleared via the lung. Recently, numerous studies have investigated the impact of PFC cell labeling on cellular phenotype and function in primary immune cells using a variety of sensitive in vitro assays, eg, in the context of human dendritic cells 30, 33 and murine T cells. 31, 34, 35 Cytotoxicity following PFC labeling was minimal, and there were no phenotypic alterations to the cells after labeling. These studies and others 34, [36] [37] [38] label cells with various PFC molecules in vitro with the goal of performing in vivo 19 F celltracking studies after cell transfer to a subject, eg, to monitor T-cell migration in experimental models of diseases. In a prior study using PFC-labeled antigen-specific T cells, we reported extra-intestinal loci of inflammation in pancreas in a mucin1
þ (MUC1 þ ) IL-10 À/À transgenic mouse model of IBD using 19 F NMR and MRI. 34 We note that in the IL-10 À/À model utilized in this study there was no evidence of pancreatitis. Quantitatively, in vitro PFC emulsion uptake by phagocytic cells, such as fetal skin-derived dendritic cells, is empirically found to be on the order of B5 Â 10 12 fluorine atoms per cell; 30 for non-phagocytic cells, such as 9 l glioma cells and T cells, uptake ranges from approximately 2 Â 10 11 to 1 Â 10 12 fluorine atoms per cell. 34, 37 Assuming that macrophages uptake B5 Â 10 12 atoms per cell in vivo, we estimate that the magnitude of macrophages in the bowel wall is of order B3 Â 10 6 cells based on our measured 19 F levels in vivo (Figure 2a) . We note that the mean PFC uptake per macrophage in vivo is not known and difficult to measure, unlike the ex vivo labeling experiments. From immunofluorescence, it is estimated that 15-20% of macrophages in the colon contained PFC-DiI.
We demonstrated that ablation of macrophages in the circulation and abdominal organs with clodronate liposomes greatly reduces 19 F signal in the colon. This result further demonstrates the selective labeling of macrophages by PFCs in vivo. Histological scoring demonstrated that macrophage ablation reduced inflammation in colon. This result indicates the importance of macrophages in the development of IBD.
We tested the prophylactic effects of two drugs, including dexamethasone and CsA, in IBD induction; the goal of these tests was to determine if 19 F MRI could be used to detect any putative therapeutic effects. Both drugs are used clinically to treat patients with IBD. 39 In our model, dexamethasone increased inflammation, especially in the descending colon, whereas CsA had a small effect on the induction of colitis. We note that facilitation of colitis with dexamethasone was also observed in the acute phase of DSS-induced colitis, 40, 41 but it ameliorated colitis in the chronic phase of DSS-induced colitis. 41 The exact mechanisms of these effects are currently not known. Differential effects of corticosteroids on the immune cells could partly explain the observed phenomenon. 42 Neutrophils, the mediators of acute inflammation, are relatively resistant to corticosteroid action and may promote the initial acute inflammation phase in piroxicam-induced intestinal damage in our model which in turn could trigger uncontrolled inflammation in an immune-deficient model such as IL-10 À/À mice. Dexamethasone is also known to aggravate the adverse gastrointestinal effects, such as perforation and bleeding, when combined with non-steroidal, anti-inflammatory drugs such as piroxicam. 43 CsA, on the other hand, reduced the severity of inflammation in the acute phase of DSS-mediated colitis by upregulating transforming growth factor-b 44 in the intestine. CsA reduces inflammation by suppressing the secretion of IL-2 by activated T cells. 45 
Activated CD4
þ T cells are the primary effectors that perpetuate colitis in IL-10 À/À mice that act synergistically with macrophages to promote inflammation. The initial induction phase of piroxicam-induced colitis in IL-10 À/À mice may be similar to acute phase of DSS-induced colitis.
In this study, we have employed a prophylactic IBD treatment model. Although, prophylactic treatment models can provide important insights into the mechanisms of disease, and in our study the basis of the 19 F MRI signal generation, we acknowledge that it is less relevant clinically. In this work, our attempt was to establish a quantitative method of measuring bowel inflammation, and therapeutic interventions were primarily used for that purpose.
The MRI-active PFC molecule (perfluoropolyether) used in this study, designed for optimal MRI sensitivity (ie, large number of NMR-equivalent 19 F's and short T 1 /T 2 ratio), has not yet been approved for clinical use. Related PFC molecules, such as perfluorooctlybromide, have been used as oxygen transport reagents in human clinical trials and have been used in MRI studies. 46, 47 However, perfluorooctylbromide is non-ideal for MRI, as it has a long T 1 and displays multiple 19 F NMR peaks, which significantly compromises sensitivity as only one single peak can be used for imaging, and the other peaks must be suppressed using pre-excitation saturation pulses. Our view is that the results presented herein help provide a rationale for pursuing the development of optimal clinical MRI diagnostic reagents for IBD that are based on PFC emulsions. Moreover, the feasibility of performing 19 F MRI scans on a clinical scanner has been demonstrated in many studies 38, 48 with the addition of a dualtuned 19 F/ 1 H radio-frequency coil. Imaging using 18 FDG PET 49 and endomicroscopic-imaging approaches 50 have also been used for quantifying bowel inflammation. 18 FDG imaging has been used in human studies. 19 F MRI may be a promising alternative to both of these techniques. 18 FDG PET measures metabolic activity and our approach measures macrophage content in the inflammatory sites. Both of these approaches are capable of measuring inflammatory activity. PET is sensitive but involves radioactive tracers, can have high background and lower spatial resolution. Moreover, it requires CT for anatomical localization. F MRI can be performed on the same instrument to obtain complementary information. Endoscopic approaches are invasive, whereas 19 F MRI is capable of 3D visualization of bowel inflammation non-invasively.
Overall, macrophages have an important role in the pathogenesis of a large number of chronic inflammatory diseases and cancers. 19 F MRI is capable of in vivo visualization and quantification of macrophage activity. We believe that in the future, 19 F MRI technology will be an effective tool for monitoring macrophage activities in disease and for assessing treatment response.
